Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology
-$0.02 today
- Market cap
- $117.90M
- Beta
- 1.22
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$7.74
Volume 0.09M
Average 0.07M
ARMP Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Armata Pharmaceuticals, Inc.AMEX: ARMP
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 80.3% from a year ago
Net receivables stood at $47K at the end of Q1 FY2026, down 80.3% from a year earlier and down 90.0% from the prior quarter. Over 3 fiscal years it compounded at -37.5% a year.
Context
- Net receivables amounted to 0.1% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -80.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 472K USD
- Year-over-year change
- -36.6%
- 4-year CAGR
- -37.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 472K | -36.6% |
| FY2024 | 2024-12-31 | 744K | -77.9% |
| FY2023 | 2023-12-31 | 3.36M | +73.7% |
| FY2022 | 2022-12-31 | 1.94M | -35.2% |
| FY2021 | 2021-12-31 | 2.99M | — |
Net Receivables vs competitors
How ARMP compares with its peers on the latest reported figures
- ARMP's Mar 2026 net receivables of $47K is the highest of the 2 companies compared; the peer median is $44K.
- Its year-over-year change of -80.3% is the highest of 2, against a peer median of -99.8%.
- Net receivables amounts to 0.1% of total assets for ARMP, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $47K | -80.3% | -37.5% | 0.1% | |
| Mar 2026 | $44K | -99.8% | +186.1% | 0.1% | |
| Peer median (excluding ARMP) | $44K | -99.8% | +186.1% | 0.1% | |
Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10.29M | 14.85M | 13.52M | 9.29M | 8.69M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 2.99M | 1.94M | 3.36M | 744K | 472K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.72M | 10.26M | 2.27M | 1.27M | 1.51M |
| Total Current Assets | 15M | 27.05M | 19.15M | 11.31M | 10.67M |
| Property, Plant & Equipment (Net) | 38.07M | 46.65M | 57.28M | 54.93M | 46.11M |
| Goodwill | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M |
| Intangible Assets | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M |
| Long-term Investments | 0 | 5.96M | 0 | 5.48M | 5.39M |
| Tax Assets | 0 | 12.04M | 0 | 0 | 0 |
| Other Non-current Assets | 2.96M | 2.43M | 8.19M | 975K | 973K |
| Total Non-current Assets | 54.77M | 80.83M | 79.21M | 75.13M | 66.21M |
| Total Assets | 69.77M | 107.88M | 98.36M | 86.44M | 76.88M |
| Account Payables | 1.14M | 6.03M | 1.59M | 766K | 921K |
| Short-term Debt | 1.51M | 17.01M | 9.48M | 38.95M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 1.29M | 529K | 1.27M |
| Total Current Liabilities | 4.81M | 24.87M | 16.46M | 48.25M | 8.95M |
| Long-term Debt | 0 | 0 | 82.31M | 55.44M | 256.92M |
| Deferred Tax Liabilities | 3.08M | 15.12M | 3.08M | 3.08M | 3.08M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 39.56M | 46.92M | 113.97M | 86.21M | 286.53M |
| Total Liabilities | 44.37M | 71.8M | 130.43M | 134.46M | 295.48M |
| Common Stock | 271K | 361K | 361K | 362K | 364K |
| Retained Earnings | (202.86M) | (239.77M) | (308.82M) | (327.74M) | (501.53M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 25.4M | 36.08M | (32.07M) | (48.02M) | (218.6M) |
| Total Debt | 37.99M | 48.82M | 120.37M | 126.52M | 288.02M |
| Net Debt | 27.7M | 33.96M | 106.85M | 117.22M | 279.33M |
Armata Pharmaceuticals, Inc.
AMEX:ARMP
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.